Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

Researchers are racing to develop treatments based on antibodies to block or neutralize the coronavirus in patients, with the hopes these could be ready for possible emergency use by the fall.

Why it matters: Many experts feel antibodies from recovered patients and synthesized antibody drugs could be important bridge treatments for COVID-19 during the months or years until a successful vaccine is available.

What's happening: Antibody therapies can be derived from human plasma or from animals that have been infected, or synthesized.

  • The idea is to bolster a person's immune system to stave off infection as a short-term prophylactic or to help an ill individual fight the disease off faster, in an effort that's been used since the 1800s, with mixed results.
  • While using any blood product can raise concerns about other infections, antibody therapies can also sometimes backfire and make conditions worse.
  • Another issue is the strength in antibodies in these donations are not necessarily consistent, adding uncertainty to its effect.
  • And, sometimes the best antibodies are missed as researchers sift through cells in search of them, says Eric Hobbs, CEO of biotech company Berkeley Lights.

Convalescent plasma, from recovered COVID-19 patients, has "investigational" status from the Food and Drug Administration. (To donate blood, check here.)

  • It's being used in various clinical trials, in research institutions and hospitals via expanded access (with roughly 11,500 patients so far), and in individuals with serious infections who receive the plasma from their physicians.
  • "The safety signal looks good" in very early preliminary data, says Michael Joyner of the Mayo Clinic, which is serving as the lead institution for the FDA's expanded access program. This correlates with indications from small prior studies.
  • "We believe this is a good biological shot on goal, but ... we have to be rigorous" in data collection, Joyner tells Axios. He expects some preliminary data to be released in a couple of weeks.
  • Beth Shaz, EVP at New York Blood Center, tells Axios they are providing plasma for patient use and for research institutions. They also are working with their hospital partners to "help figure out what type of antibody is best for impacting patient outcomes."

Monoclonal antibody drugs are also being developed to target specific proteins or functions of the SARS-CoV-2 virus to neutralize and/or block it. There are at least 50 candidates in development, including by Regeneron and Eli Lilly.

  • "The good thing about a monoclonal is you can give it to sick patients immediately, and it should have an immediate effect. And you can also give it as a sort of temporary vaccine, because antibodies can stay in the bloodstream for weeks and sometimes even months," says Derek Lowe, a drug discovery scientist who wrote a blog on this for Science Translational Medicine.

One of the problems with this coronavirus is that scientists don't yet know which part of SARS-CoV-2 is best to target.

  • A majority of monoclonal antibody research is targeting part of the spike protein, with some aiming for the receptor-binding domain (RBD), Lowe says.
  • But, an intriguing early stage study released earlier this week may shed some light on how the virus works, he adds.
  • In this study — which was only done in cell cultures and must still be tested in both animals and humans — researchers developed a monoclonal antibody called 47D11 that successfully blocked both viruses that cause COVID-19 and SARS.
  • Lowe said the neutralizing antibody was able to bind to the spike and bind to the RBD — but this wasn't what prevented the virus from infecting the human cell. "It did stop the virus from infecting the cell because it messes up the next step, via some mechanism we don't understand yet."
  • Meanwhile, another early stage study out this week shows early signs that smaller-sized llama antibodies could lead to new drug targets to neutralize SAVS-CoV-2.

What to watch: Technology is speeding up the research.

  • Berkeley Lights has developed technology that can deep screen live cells to find the best antibody therapeutic candidates — all within roughly 10 hours, which compares to 90 days via current technology, the CEO tells Axios. While expensive (roughly $2 million a tool), "it's significantly faster ... and, in pandemics, time matters," Hobbs adds.
  • Lowe says screening technology like that "has been a big change over the years — people have gotten a lot better at finding and isolating the cells that produce these things."

The bottom line: While significant research remains to be done, there's hope antibody therapies may offer the first round of effective treatments for this pandemic.

Go deeper

Aug 15, 2020 - Health

FDA releases first-ever list of medical supplies in shortage

A medical worker handling a coronavirus test in Charlestown, Massachusetts, on Aug. 11. Photo: Matt Stone/ MediaNews Group/Boston Herald

The Food and Drug Administration on Friday released its first-ever list of medical devices needed to respond to the coronavirus that are in short supply.

Why it matters: The list includes surgical gowns, gloves, masks, certain ventilators and testing supplies that medical workers require to effectively respond to the pandemic, which has infected more than 5.3 million people in the U.S. to date, according to Johns Hopkins University.

Updated Oct 7, 2020 - Health

World coronavirus updates

Expand chart
Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

New Zealand now has active no coronavirus cases in the community after the final six people linked to the Auckland cluster recovered, the country's Health Ministry confirmed in an email Wednesday.

The big picture: The country's second outbreak won't officially be declared closed until there have been "no new cases for two incubation periods," the ministry said. Auckland will join the rest of NZ in enjoying no domestic restrictions from late Wednesday, Prime Minister Jacinda Ardern said, declaring that NZ had "beat the virus again."

Updated 11 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: FDA approves Pfizer boosters for high-risk individuals, people 65 and up — Team USA to mandate vaccine for Winter Olympic hopefuls — U.S. to buy 500 million more Pfizer doses to share with the world.
  2. Health: Some experts see signs of hope as cases fall — WHO: Nearly 1 in 4 Afghan COVID hospitals shut after Taliban takeover — D.C. goes further than area counties with vaccine mandates.
  3. Politics: Bolsonaro isolating after health minister tests positive at UN summit — United Airlines says 97% of U.S. employees fully vaccinated — Mormon Church to mandate masks in temples.
  4. Education: Asymptomatic Florida students exposed to COVID no longer have to quarantine — Education Department investigating Texas mask mandate ban — D.C. schools to require teachers, staff to receive vaccine without testing option.
  5. Variant tracker: Where different strains are spreading.